Quanterix Corporation — 2020 Form 10-K Summary
Business context and reporting period
Quanterix develops and sells ultra-sensitive Simoa protein-detection platforms, assays, consumables and research services, primarily for life-sciences research. The filing covers the fiscal year ended December 31, 2020; fourth-quarter figures are also summarized below. Its business includes the HD-X and SR-X bead-based instruments, the SP-X planar-array instrument, the Accelerator Laboratory and Uman’s Nf-L antibodies and ELISA kits.
Key financial results
| Metric | FY 2020 | FY 2019 |
|---|---|---|
| Total revenue | $86.4 million | $56.7 million |
| Gross profit / gross margin | $48.2 million / 56% | $26.8 million / 47% |
| Operating expenses | $79.8 million | $68.4 million |
| Operating loss | $31.6 million | $41.6 million |
| Net loss | $31.5 million | $40.8 million |
| Net cash used in operating activities | $23.4 million | $26.2 million |
| Cash and cash equivalents at year-end | $181.6 million | $109.2 million |
| Debt at year-end | $7.7 million | $7.7 million |
Revenue comprised $44.0 million of product sales, $24.1 million of service and other revenue, $11.8 million of collaboration and license revenue, and $6.4 million of grant revenue. Consumables revenue was $27.4 million, about 32% of total revenue. Quanterix reported a $31.5 million accumulated deficit and $206.1 million of stockholders’ equity at year-end. Cash, cash equivalents and restricted cash totaled $182.6 million.
In Q4 2020, revenue was $26.1 million, compared with $15.9 million in Q4 2019. Gross profit was $15.1 million and net loss was $9.8 million in Q4 2020, versus $6.9 million and $11.0 million, respectively, in Q4 2019. Q3 2020 included a $10.0 million Abbott license fee and $1.9 million of grant revenue; these items contributed to that quarter’s reported operating profit.
Material changes versus prior year
- Revenue increased 52%, driven by higher instrument and consumables sales, increased Accelerator Laboratory activity, the Abbott license and NIH grant revenue.
- Product revenue rose 9% to $44.0 million; instrument revenue was $16.6 million and consumables revenue was $27.4 million. The company attributed consumables growth to a larger installed instrument base.
- Service and other revenue increased 50% to $24.1 million, primarily from greater research-services utilization and warranty sales.
- Gross margin rose to 56% from 47%, principally because license and grant revenue expanded faster than costs; do not assume this margin improvement reflects only recurring product economics.
- Operating expenses increased 17% to $79.8 million, including higher R&D and SG&A spending as the company expanded its organization. Net loss narrowed by $9.3 million.
- Operating cash use declined to $23.4 million from $26.2 million. Financing activities provided $96.2 million, primarily from the 2020 public offering; the company also spent $0.6 million net on investing activities.
Outlook, commentary and risks
Management expected continued operating losses and significant expenses, with plans to invest in sales, marketing, R&D, personnel and product development. It stated in the liquidity discussion that available resources were expected to fund operations for at least 12 months; elsewhere, the filing discusses a longer runway based on cash together with commercial sales. These estimates are forward-looking and subject to risk.
On February 3, 2021, after year-end, Quanterix completed an offering that generated approximately $269.6 million in net proceeds. The filing does not provide a subsequent cash balance. The Hercules term loan was scheduled for repayment in 2021; $7.7 million of principal was current at year-end, with payments scheduled from July through October 2021.
- The FDA granted Emergency Use Authorizations for the Simoa SARS-CoV-2 IgG antibody test in December 2020 and the N-protein antigen test in January 2021. EUAs may be revised or revoked, and the products’ market acceptance and demand are uncertain.
- The NIH RADx Workplan 2 award had a total value of $18.2 million, subject to milestones and a contract period through September 2021. The company recognized $4.4 million of Workplan 2 grant revenue in 2020; full funding was not assured.
- COVID-19 disrupted customer access, instrument installations and some laboratory activity. Management said these effects could continue until customers resumed normal operations.
- Quanterix has incurred annual losses since inception and expected losses to continue. Key business risks include market adoption, competition, dependence on Nf-L-related revenue, regulatory requirements, and reliance on sole or limited-source instrument and component suppliers.
- FDA clearance or approval would generally be required for clinical diagnostic products beyond the COVID-19 EUAs. The company’s other products were primarily labeled for research use only.
- No material legal proceedings were reported. The company reported effective disclosure controls and management concluded internal control over financial reporting was effective; the auditor did not provide an internal-control attestation.
Important facts for investors to verify
- How much of future growth and gross margin is supported by recurring consumables and services versus one-time license fees and milestone-dependent grants?
- Whether the Abbott license generates development milestones or royalties, and whether NIH RADx milestones are achieved and remaining funds collected.
- Post-offering cash, operating cash burn and the company’s funding runway, including repayment of the Hercules debt in 2021.
- COVID-test demand, continuing EUA status, and any additional regulatory authorizations or sample-type expansions.
- Instrument placements, utilization, consumables attachment and Nf-L-related revenue concentration; the filing estimates Nf-L services and consumables represented about 8% of 2020 revenue.
- Potential supply interruptions from single-source manufacturers and suppliers, and the timing and cost of any replacement qualification.